CN1814216A - Chinese medicine composition for diminishing speckle and pox - Google Patents
Chinese medicine composition for diminishing speckle and pox Download PDFInfo
- Publication number
- CN1814216A CN1814216A CN 200510022714 CN200510022714A CN1814216A CN 1814216 A CN1814216 A CN 1814216A CN 200510022714 CN200510022714 CN 200510022714 CN 200510022714 A CN200510022714 A CN 200510022714A CN 1814216 A CN1814216 A CN 1814216A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- pharmacy
- prepared
- pox
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese medicinal combination for dispelling freckle and pox, prepared mainly from seed of Job's tears, ahurian Angelica Root, Lily Bulb, Hawthorn Fruit (charred), Safflower, Rice Bean, Fructus Gardeniae, Haichow Elsholtzia Herb, Maren, Perilla frutescens ( L. ) Britt, Common Floweringqince Fruit, Immature Bitter Orange, Chrysanthemum and Peppermint into any form by routine process in the pharmacy of Chinese medicine. And the clinic and lab data indicate that it has remarkable curative effect on chloasma and acne; and has a certain relieving and health protecting function on dysmenorrhea, catamenia, adnexitis and premature senility of skin and feature. In addition, it also has a certain relieving and health protecting function on urticaria, papular urticaria, allergic skin disease, and allergic rhinitis.
Description
Technical field
The present invention relates to Chinese herbal and crude drugs preparations of a kind of endocrine regulation function and preparation method thereof, relate in particular to a kind of Chinese herbal medicine oral formulations of diminishing speckle and pox skin maintenance.
Technical background
Chloasma is that good sending out decreased U.S. dermatoses in the filbert of young and middle-aged women face or yellowish-brown pigmentation, and its predisposing factors has tens of more than, however basic factor be mainly endocrine function imbalance and interior each organ function of body not in tune due to.Acne is that good sending out decreased U.S. dermatoses in the common pilosebaceous unit chronic inflammation of adolescence, and its predisposing factors is a lot, yet basic factor still is mainly the endocrine function imbalance and interior each organ function of body is not in tune.
Though chloasma belongs to the not normal dermatoses of metabolism of pigment, acne is the skin appendages dermatosis, yet it has following general character: 1. the two belongs to the head-face skin problem; 2. the morbidity basic factor of the two all belongs to endocrine function imbalance and interior each organ function of body is not in tune; 3. the skin metabolism function reduces and can cause women's head-ornaments portion damage U.S.'s property dermatopathy; 4. motherland's medical science think the two morbidity all with dash to appoint that mistake is foster, disharmony between QI and blood, taste are uncomfortable, deficiency of both the lung and kidney, the exterior and the interior are become estranged, stagnation of QI due to depression of the liver is relevant.So the two can adopt same Chinese herbal and crude drugs preparations conditioning and treating.
At present, mainly adopt external treatment for chloasma and remedy of acne, but no matter topical agent, cosmetics for external use, disinfectant preparation, it all has following defective: 1. cure the symptoms, not the disease, be easy to repeatedly; 2. side effect is arranged, be unfavorable for skin health.Though the part Orally taken product is also arranged on the market, yet its quality, effect are all unstable, moreover the Chinese herbal and crude drugs preparations that combines together as diminishing speckle and pox is also rarely found.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition that is used for diminishing speckle and pox.
The present invention is used for the Chinese medicine composition of diminishing speckle and pox, mainly is to be prepared from by following raw materials by weight percent:
Semen Coicis 1-60% Radix Angelicae Dahuricae 1-60% Bulbus Lilii 1-60% Fructus Crataegi (parched to brown) 1-60%
Flos Carthami 1-60% Semen Phaseoli 1-60% SHANZHIZI 1-60% Herba Moslae 1-60%
Fructus Cannabis 0-30% Folium Perillae 1-60% Fructus Chaenomelis 0-60% Fructus Aurantii Immaturus 0-60%
Flos Chrysanthemi 0-60% Herba Menthae 0-60%
The preferred weight percent of each raw material is in the described Chinese medicine composition:
Semen Coicis 2-15% Radix Angelicae Dahuricae 2-15% Bulbus Lilii 2-15% Fructus Crataegi (parched to brown) 2-15%
Flos Carthami 5-10% Semen Phaseoli 5-10% SHANZHIZI 5-10% Herba Moslae 5-10%
Fructus Cannabis 5-10% Folium Perillae 5-10% Fructus Chaenomelis 5-10% Fructus Aurantii Immaturus 5-10%
Flos Chrysanthemi 5-10% Herba Menthae 5-10%
Described Chinese medicine composition adopts the common process of pharmacy of Chinese materia medica to be prepared into capsule.
Described Chinese medicine composition adopts the common process of pharmacy of Chinese materia medica to be prepared into powder or electuary.
Described Chinese medicine composition adopts the common process of pharmacy of Chinese materia medica to be prepared into watered pill or honey pill agent or water-honeyed pill or concentrated pill or drop pill.
Described Chinese medicine composition adopts the conventional production process of pharmacy of Chinese materia medica to be prepared into tablet.
Described Chinese medicine composition adopts the conventional production process of pharmacy of Chinese materia medica to be prepared into distillate medicinal water or oral solutions.
Described Chinese medicine composition adopts the conventional production process of pharmacy of Chinese materia medica to be prepared into lozenge or medicinal tea.
The mechanism of action of herbal composite of the present invention: function of spleen and stomach regulating, Tongli removing the relative excess; Chong and Ren Meridians regulating, promoting flow of QI and blood; Reinforce insufficiency and reduce excessiveness, mediation the exterior and the interior; Soothing liver-QI for relieving depression, harmonizing the functional activities of vital QI; Flourish outer, diminishing speckle and pox, skin maintenance in transferring.
Effect of the present invention:
(1) the present invention is to the treatment of chloasma: concrete therapeutic effect can obtain proving by the clinical and laboratory data of Food Hygiene Surveillance check institute of Ministry of Health of the People's Republic of China.
1. object and method
1.1 tried thing: capsule of the present invention is provided by Gansu Qingdai Chinese Herbal Medicine Beauty Research Co., Ltd..
1.2 study subject: press the principle of voluntariness and select 18-65 year, have chloasma experimenter 30 examples.
1.2.1 diagnostic criteria: the visible brown spot of women's head-ornaments portion perusal is mainly in and cheekbone, cheek, volume, nose, lip week etc. locates symptoms such as no sufferings.
1.2.2 the person's of including in standard: all volunteers that chloasma is arranged, all can carry out test-meal through medical fitness and observe.
1.2.3 eliminator's standard
1.2.3.1 the age, gestation or women breast-feeding their children were to these health product allergy sufferers under-18s or over-65s person.
1.2.3.2 be associated with the serious primary disease of conscience kidney and hemopoietic system, the psychotic has a liking for cigarette, wine person.
1.2.3.3 do not meet the standard of including in, not medication in accordance with regulations can't be judged curative effect or data not umbra sound curative effect or safety judgement person.
1.3 contrast form: adopt self cross-reference form.
1.4 instructions of taking: every day 2 times, each 2-3 grain, every 0.3 gram, one after each meal, continuous 30 days, the experimenter cut out other health product and uses the cosmetics of relevant face-beautifying and spot-removing at experimental session.
1.5 instrument and reagent: F-820 type blood counting instrument, urinate ten analysers (German Bao Ling Man produce), AMS semi-automatic biochemical analyzer (Italy produces), the Beijing Nuclear Instrument Factory produces full-automatic γ calculating instrument, model FT-630G, Institute of Geography, Academia Sinica's development and design, Mapping Press published " practical standard colour atla " (front page) in 1992, the biochemical reagents box is all provided by middle living company, and SOD radioimmunoassay determination medicine box is provided by the Beijing North biotechnology research.
2. observation index
Each is checked once before and after the experiment.
2.1 effect observation
2.1.1 ordinary circumstance
Detailed medical history-taking is understood patient's diet situation, and activity is observed main clinic symptoms: insomnia, feeling of fatigue, distending pain in the chest and hypochondrium, loose stool, constipation etc.Before and after test-meal, add up score value by symptom weight (serious symptom 3 minutes, moderate 2 minutes, light disease 1 minute), and improve (2 fens produce effects of each doing well,improving are improved 1 and are divided into effectively), calculate the improvement rate with regard to its cardinal symptom.
2.1.2 women's head-ornaments portion chloasma detects
2.1.2.1 the area size changes: major diameter and wide footpath before and after being tried with the same chloasma of tape measure, reference area (mm
2).
2.1.2.2 shade changes
According to Institute of Geography, Academia Sinica's development and design, brown (Y+M+Bk i.e. Huang+magenta+black folded color) colour atla in " practical standard colour atla " (front page) that Mapping Press published in 1992 is the criterion of chloasma shade: I degree (15,20,5), II degree (30,40,10), III degree (40,60,15).
2.2 chloasma position photo
2.3 superoxide dismutase (SOD) and malonaldehyde (MDA) assay.
2.4 safety is observed
2.4.1 blood and routine urianlysis
Red blood cell count(RBC), hemoglobin, numeration of leukocyte is urinated ten detections.
2.4.2 biochemical indicator is measured
Serum albumin ALB, total protein TB, darling renal function (glutamic oxaloacetic transaminase, GOT AST, glutamate pyruvate transaminase ALT, blood urea nitrogen BUN, inosine Cre), blood glucose GLU, blood fat (T-CHOL TC, triglyceride TG, HDL-C HDL-C).
2.4.3 Abdominal B type ultrasonography, electrocardiogram, the fluoroscopy of chest of X line.
3. spot-removal function is judged
Produce effects: chloasma color decline II degree, or area dwindle＞1/3, do not produce new chloasma, SOD, MDA are changed significantly.
Effectively: chloasma color decline I degree, area dwindle≤and 1/3, do not produce new chloasma, SOD raises, and MDA descends.
Invalid: chloasma color and area do not have significant change.
4. experimental result
4.1 ordinary circumstance
Observing chloasma experimenter 30 examples altogether, all is the women, minimum 23 years old of age, maximum 58 years old, average 41.13 ± 8.05 years old, average course of disease 6.85 ± 5.50 years.
4.2 changing, the chloasma shade sees Table 1
Table 1. chloasma shade changes
| The example number | Before the test-meal | After the test-meal | |
| Colour atla (degree) | 30 | 2.1±0.48 | 1.30±0.47 *** |
***P＜0.001
4.3 chloasma area size variation sees Table 2
Table 2. chloasma area size variation
| The example number | Before the test-meal | After the test-meal | Difference | |
| Chloasma area (mm 2) | 30 | 56.28±33.02 | 27.54±22.59 | 28.73±17.32 *** |
***P＜0.001
4.4SOD, the MDA changes of contents sees Table 3
Change before and after table 3.SOD, the MDA test-meal
| Project | The example number | Before being tried | After being tried |
| SOD(ng/ml) MDA(nmol/L) | 30 30 | 172.27±83.87 56.09±20.75 | 332.45±289.81 ** 44.61±15.77 * |
*P＜0.05
**P＜0.01
4.5 the effect evaluation sees Table 4
Table 4. effect is judged
| Produce effects | Effectively | Invalid | Total effective rate (%) | |
| Example number effect rate (%) | 5 16.67 | 18 60.00 | 7 23.33 | 23 76.67 |
4.6 the doing well,improving situation sees Table 5
Table 5. cardinal symptom is improved situation
| Cardinal symptom | The example number | Produce effects | Effectively | Invalid | Total effective rate (%) |
| The irritated distending pain in the chest and hypochondrium constipation of feeling of fatigue | 20 21 12 16 | 8 2 2 5 | 7 12 6 7 | 5 7 4 4 | 75.00 66.67 66.67 68.75 |
4.7 changing, symptom integral sees Table 6
Table 6. symptom integral changes
| The example number | Before the test-meal | In the test-meal | After the test-meal |
| 30 | 5.73±3.54 | 3.83±3.30 *** | 2.67±2.89 *** |
***P＜0.001
4.8 safety indexes detects and sees Table 7
Table 7. safety indexes detects
| Project | The example number | Before the test-meal | After the test-meal |
| TP(g/L) ALB(g/L) ALT(u/L) AST(u/L) GLU(mmol/L) TC(mmol/L) TG(mmol/L) HDL-C(mmol/L) BUN(mmol/L) CRE(mmol/L) HGB(g/L) RBC(×10 12/L) WBC(×10 9/ L) urinate ten | 30 30 30 30 30 30 30 30 30 30 30 30 30 30 | 77.36 ± 3.03 51.54 ± 3.35 26.87 ± 8.11 35.33 ± 7.12 4.65 ± 1.08 5.15 ± 1.21 1.30 ± 0.80 1.58 ± 0.42 5.48 ± 1.38 74.42 ± 12.46 142.5 ± 7.30 4.92 ± 0.35 5.83 ± 0.92 is normal | 77.66 ± 4.88 50.94 ± 3.22 30.70 ± 12.16 37.07 ± 6.43 5.12 ± 0.89 5.26 ± 1.08 1.47 ± 0.76 1.43 ± 0.38 5.05 ± 1.26 74.54 ± 13.69 142.9 ± 6.97 4.93 ± 0.39 5.70 ± 1.38 is normal |
4.9 examination trencherman electrocardiogram before and after the test-meal, Abdominal B type ultrasonography, the X-ray Chest X-rays all belongs to normal range.
5. conclusion
5.1 30 routine chloasma experimenters took capsule of the present invention 30 days on request, the chloasma color shoals, and area on average dwindles 28.73 ± 17.32mm
2, colour atla on average reduces by 0.80 ± 0.41 degree, produce effects 5 examples wherein, and effective 18 examples, total effective rate 76.67% illustrates that capsule of the present invention has the effect of spot-removing beautifying face.
5.2 capsule of the present invention can improve SOD and reduce MDA content, and compares before the test-meal that there were significant differences.
5.3 capsule of the present invention has the improvement effect to symptoms such as chloasma experimenter feeling of fatigue, distending pain in the chest and hypochondrium, constipation.
5.4 before and after the capsule test-meal of the present invention, hemoglobin, erythrocyte, leukocyte, total serum protein, albumin, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, inosine, blood urea nitrogen, blood glucose, blood fat etc. illustrate that all in normal range this product has no adverse effects to health.
5.5 do not observe anaphylaxis and other untoward reaction in the capsule test-meal process of the present invention.
(2), the present invention is to remedy of acne: concrete curative effect can obtain proving by the clinical and laboratory data of Food Hygiene Surveillance check institute of Ministry of Health of the People's Republic of China.
1. object and method
1.1 tried thing: capsule of the present invention is provided by Gansu Qingdai Chinese Herbal Medicine Beauty Research Co., Ltd..
1.2 study subject: press the principle of voluntariness and select 18-65 year, have acne experimenter 30 examples.
1.2.1 diagnostic criteria: with reference to Wang Jisheng chief editor, Tianjin science and technology publishing house 1987 the 1st edition " practical skin science ".
1.2.2 the person's of including in standard: all volunteers that acne is arranged, all can carry out test-meal through medical fitness and observe.
1.2.3 eliminator's standard
1.2.3.1 the age, gestation or women breast-feeding their children were to these health product allergy sufferers under-18s or over-65s person.
1.2.3.2 be associated with the serious primary disease of conscience kidney and hemopoietic system, the psychotic has a liking for cigarette, wine person.
1.2.3.3 do not meet the standard of including in, not medication in accordance with regulations can't be judged curative effect or data not umbra sound curative effect or safety judgement person.
1.3 contrast form: adopt self cross-reference form.
1.4 taking dose and time: every day 2 times, each 3, every 0.3 gram, one after each meal, continuous 30 days, the experimenter stopped using other articles for use oral and the relevant treatment of external acne at duration of test.
1.5 instrument and reagent: F-820 type blood counting instrument, urinate ten analysers (German Bao Ling Man produce), AMS semi-automatic biochemical analyzer (Italy produces), the biochemical reagents box is all provided by middle living company.
2. observation index
Each is checked once before and after the experiment.
2.1 effect observation
2.1.1 ordinary circumstance
Detailed medical history-taking is observed main clinic symptoms: appetite, sleep, feeling of fatigue, distending pain in the chest and hypochondrium, loose stool, constipation etc.Symptom weight (serious symptom 3 minutes, moderate 2 minutes, light disease 1 minute) is added up integrated value before and after test-meal, and improves (each doing well,improving 2 is divided into produce effects, improves 1 and is divided into effectively) with regard to its cardinal symptom, calculates the improvement rate.
2.1.2 women's head-ornaments portion acne detects
Press the acne typoiogical classification before and after the test-meal, and count the number of all kinds of acnes.
2.2 safety is observed
2.2.1 blood and routine urianlysis
Red blood cell count(RBC), hemoglobin, numeration of leukocyte is urinated ten detections.
2.2.2 biochemical indicator is measured
Serum albumin ALB, total protein TB, the heart, liver, renal function (glutamic oxaloacetic transaminase, GOT AST, glutamate pyruvate transaminase ALT, blood urea nitrogen BUN, inosine Cre), blood glucose GLU, blood fat (T-CHOL TC, triglyceride TG, HDL-C HDL-C).
2.4.3 Abdominal B type ultrasonography, electrocardiogram, the fluoroscopy of chest of X line.
3. effect is judged
Produce effects: skin lesion decreased number 〉=70%.
Effectively: skin lesion decreased number 〉=30%.
Invalid: skin lesion decreased number＜30%.
4. result of the test
4.1 general situation
Observe acne experimenter 30 examples altogether, male's 5 examples, women's 25 examples, minimum 16 years old of age, maximum 41 years old, average 26.77 ± 6.81 years old, average course of disease 4.23 ± 4.16 years.
4.2 changing, facial acne sees Table 8
Acne changes before and after table 8. test-meal
| Project | The example number | Before the test-meal | After the test-meal |
| Struvite pimple hoary hair's acne blackhead tuberosity cyst | 30 23 15 10 5 | 12.57±8.19 5.91±7.60 7.93±7.65 5.10±2.85 4.0±3.54 | 7.40±7.09 *** 2.70±3.74 * 3.13±2.98 ** 3.30±1.77 ** 0.60±0.548 |
*P＜0.05
**P＜0.01
***P＜0.001
4.3 the effect evaluation sees Table 9
Table 9. effect is judged
| Produce effects | Effectively | Invalid | Total effective rate (%) | |
| Example number effect rate (%) | 7 23.33 | 18 60.00 | 5 16.67 | 25 83.33 |
4.4 the doing well,improving situation sees Table 10
Table 10. cardinal symptom is improved situation
| Cardinal symptom | The example number | Produce effects | Effectively | Invalid | Total effective rate (%) |
| The irritated constipation of insomnia feeling of fatigue | 11 12 16 17 | 3 1 4 3 | 5 8 7 12 | 3 3 5 2 | 72.73 75.00 68.75 88.24 |
4.5 changing, symptom integral sees Table 11
Table 11. symptom integral changes
| The example number | Before the test-meal | In the test-meal | After the test-meal |
| 30 | 5.87±3.78 | 3.93±2.99 *** | 2.50±2.08 *** |
***P＜0.001
4.6 safety indexes detects and sees Table 12
Table 12. safety indexes detects
| Project | The example number | Before the test-meal | After the test-meal |
| TP(g/L) ALB(g/L) ALT(u/L) AST(u/L) GLU(mmol/L) TC(mmol/L) | 30 30 30 30 30 30 | 77.01±3.11 52.49±2.40 26.43±7.93 32.49±7.49 4.62±0.39 4.40±0.64 | 77.50±4.01 51.86±2.74 28.72±8.84 36.13±6.96 4.63±0.37 4.69±0.88 |
| TG(mmol/L) HDL-C(mmol/L) BUN(mmol/L) CRE(mmol/L) HGB(g/L) RBC(×10 12/L) WBC(×10 9/ L) urinate ten | 30 30 30 30 30 30 30 30 | 1.09 ± 0.72 1.46 ± 0.35 5.06 ± 1.49 70.12 ± 8.66 144.70 ± 11.39 4.86 ± 0.49 6.41 ± 1.06 is normal | 1.16 ± 0.50 1.51 ± 0.39 5.01 ± 1.41 73.13 ± 17.77 145.93 ± 11.88 4.97 ± 0.56 6.09 ± 1.03 is normal |
4.7 Abdominal B type ultrasonography, electrocardiogram, the Chest X-rays of X line detects: all belong to normal range before and after the test-meal.
5. conclusion
5.130 routine acne experimenter took capsule of the present invention 30 days on request, the acne decreased number, and the skin lesion degree alleviates, produce effects 7 examples wherein, effective 18 examples, total effective rate 83.33% illustrates that capsule of the present invention has the effect of the acne of dispelling.
5.2 capsule of the present invention has the improvement effect to symptoms such as acne experimenter's insomnia, feeling of fatigue, distending pain in the chest and hypochondrium, constipation.
5.3 before and after the capsule test-meal of the present invention, hemoglobin, erythrocyte, leukocyte, total serum protein, albumin, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, inosine, blood urea nitrogen, blood glucose, blood fat etc. illustrate that all in normal range this product has no adverse effects to the experimenter.
5.4 capsule of the present invention is not observed allergy and other untoward reaction in the test-meal process.
(3), Chinese medicine composition of the present invention has certain alleviation health-care effect to women's premenstrual tension syndrome.
(4), Chinese medicine composition of the present invention has certain alleviation health-care effect to skin appearance senilism disease.
(5), Chinese medicine composition of the present invention has certain alleviation health-care effect to urticaria, papular urticaria, anaphylaxis dermatosis, allergic rhinitis.
(6), Chinese medicine composition of the present invention has certain alleviation health-care effect to dysmenorrhea, menoxenia, adnexitis.
The specific embodiment
Embodiment 1: the preparation of capsule of the present invention
Prescription: (in weight ratio)
Semen Coicis 60% Radix Angelicae Dahuricae 10% Bulbus Lilii 10% Fructus Crataegi (parched to brown) 10%
Flos Carthami 1% Semen Phaseoli 1% SHANZHIZI 1% Herba Moslae 1%
Fructus Cannabis 1% Folium Perillae 5%
Technology: press the formula optimization medical material, clean out for all, add twice of dried up decoction (each two hours), collecting decoction filters, and removes slag, and concentrates, and is centrifugal, reconcentration, and 60 ℃ of vacuum dryings are pulverized, and sieve, and are encapsulated, are up to the standards and dispatch from the factory.Or directly this herbal composite being crushed to the 100-120 order, degerming is encapsulated, is up to the standards to dispatch from the factory.
Embodiment 2: the preparation of powder of the present invention or electuary
Prescription: (in weight ratio)
Semen Coicis 5% Radix Angelicae Dahuricae 10% Bulbus Lilii 10% Fructus Crataegi (parched to brown) 5%
Flos Carthami 10% Semen Phaseoli 10% SHANZHIZI 10% Herba Moslae 10%
Fructus Cannabis 5% Folium Perillae 5% Fructus Chaenomelis 5% Fructus Aurantii Immaturus 5%
Flos Chrysanthemi 5% Herba Menthae 5%
Technology: by above-mentioned formula optimization medical material, screening is cleaned, and is prepared into powder or electuary according to the common process of producing powder or electuary on the pharmacy of Chinese materia medica, degerming, and packing is up to the standards and dispatches from the factory.
Embodiment 3: the preparation of watered pill of the present invention or honey pill agent or water-honeyed pill or concentrated pill or drop pill
Prescription: (in weight ratio)
Semen Coicis 2% Radix Angelicae Dahuricae 5% Bulbus Lilii 5% Fructus Crataegi (parched to brown) 5%
Flos Carthami 10% Semen Phaseoli 10% SHANZHIZI 10% Herba Moslae 10%
Fructus Cannabis 10% Folium Perillae 10% Fructus Chaenomelis 10% Fructus Aurantii Immaturus 10%
Flos Chrysanthemi 2% Herba Menthae 1%
Technology: by above-mentioned formula optimization medical material, screening is cleaned, and is prepared into watered pill or honey pill agent or water-honeyed pill or concentrated pill, degerming according to the common process of producing watered pill or honey pill agent or water-honeyed pill or concentrated pill or drop pill on the pharmacy of Chinese materia medica, packing is up to the standards and dispatches from the factory.
Embodiment 4: the preparation of tablet of the present invention
Prescription: (in weight ratio)
Semen Coicis 15% Radix Angelicae Dahuricae 15% Bulbus Lilii 15% Fructus Crataegi (parched to brown) 15%
Flos Carthami 2% Semen Phaseoli 2% SHANZHIZI 2% Herba Moslae 2%
Fructus Cannabis 2% Folium Perillae 5% Fructus Chaenomelis 5% Flos Chrysanthemi 10%
Herba Menthae 10%
Technology: by above-mentioned formula optimization medical material, screening is cleaned, and is prepared into tablet according to the common process of producing tablet on the pharmacy of Chinese materia medica, degerming, and packing is up to the standards and dispatches from the factory.
Embodiment 5: the preparation of distillate medicinal water of the present invention or oral solutions
Prescription: (in weight ratio)
Semen Coicis 1% Radix Angelicae Dahuricae 15% Bulbus Lilii 15% Fructus Crataegi (parched to brown) 5%
Flos Carthami 7% Semen Phaseoli 8% SHANZHIZI 7% Herba Moslae 8%
Fructus Cannabis 7% Folium Perillae 8% Fructus Chaenomelis 8% Fructus Aurantii Immaturus 7%
Flos Chrysanthemi 2% Herba Menthae 2%
Technology: by above-mentioned formula optimization medical material, screening is cleaned, and is prepared into distillate medicinal water or oral solutions according to the common process of production distillate medicinal water or oral solutions on the pharmacy of Chinese materia medica, degerming, and packing is up to the standards and dispatches from the factory.
Embodiment 6: the preparation of lozenge of the present invention or medicinal tea
Prescription: (in weight ratio)
Semen Coicis 7% Radix Angelicae Dahuricae 8% Bulbus Lilii 8% Fructus Crataegi (parched to brown) 7%
Flos Carthami 7% Semen Phaseoli 8% SHANZHIZI 7% Herba Moslae 8%
Fructus Cannabis 7% Folium Perillae 8% Fructus Chaenomelis 8% Fructus Aurantii Immaturus 7%
Flos Chrysanthemi 5% Herba Menthae 5%
Technology: by above-mentioned formula optimization medical material, screening is cleaned, and is prepared into lozenge or medicinal tea according to the common process of producing lozenge or medicinal tea on the pharmacy of Chinese materia medica, degerming, and packing is up to the standards and dispatches from the factory.
Specific embodiments of the invention also have a lot, repeat no more here.
Claims (8)
1, a kind of Chinese medicine composition that is used for diminishing speckle and pox mainly is to be prepared from by following raw materials by weight percent:
Semen Coicis 1-60% Radix Angelicae Dahuricae 1-60% Bulbus Lilii 1-60% Fructus Crataegi (parched to brown) 1-60%
Flos Carthami 1-60% Semen Phaseoli 1-60% SHANZHIZI 1-60% Herba Moslae 1-60%
Fructus Cannabis 0-30% Folium Perillae 1-60% Fructus Chaenomelis 0-60% Fructus Aurantii Immaturus 0-60%
Flos Chrysanthemi 0-60% Herba Menthae 0-60%.
2, be used for the Chinese medicine composition of diminishing speckle and pox according to claim 1, it is characterized in that: the preferred weight percent of each raw material is in the described Chinese medicine composition:
Semen Coicis 2-15% Radix Angelicae Dahuricae 2-15% Bulbus Lilii 2-15% Fructus Crataegi (parched to brown) 2-15%
Flos Carthami 5-10% Semen Phaseoli 5-10% SHANZHIZI 5-10% Herba Moslae 5-10%
Fructus Cannabis 5-10% Folium Perillae 5-10% Fructus Chaenomelis 5-10% Fructus Aurantii Immaturus 5-10%
Flos Chrysanthemi 5-10% Herba Menthae 5-10%.
3, be used for the Chinese medicine composition of diminishing speckle and pox according to claim 1, it is characterized in that: adopt the common process of pharmacy of Chinese materia medica to be prepared into capsule.
4, be used for the Chinese medicine composition of diminishing speckle and pox according to claim 1, it is characterized in that: adopt the common process of pharmacy of Chinese materia medica to be prepared into powder or electuary.
5, be used for the Chinese medicine composition of diminishing speckle and pox according to claim 1, it is characterized in that: adopt the common process of pharmacy of Chinese materia medica to be prepared into watered pill, honey pill agent, water-honeyed pill, concentrated pill or drop pill.
6, be used for the Chinese medicine composition of diminishing speckle and pox according to claim 1, it is characterized in that: adopt the conventional production process of pharmacy of Chinese materia medica to be prepared into tablet.
7, be used for the Chinese medicine composition of diminishing speckle and pox according to claim 1, it is characterized in that: adopt the conventional production process of pharmacy of Chinese materia medica to be prepared into distillate medicinal water or oral solutions.
8, be used for the Chinese medicine composition of diminishing speckle and pox according to claim 1, it is characterized in that: adopt the conventional production process of pharmacy of Chinese materia medica to be prepared into lozenge or medicinal tea.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100227143A CN100360168C (en) | 2005-12-14 | 2005-12-14 | Chinese medicine composition for diminishing speckle and pox |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100227143A CN100360168C (en) | 2005-12-14 | 2005-12-14 | Chinese medicine composition for diminishing speckle and pox |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1814216A true CN1814216A (en) | 2006-08-09 |
| CN100360168C CN100360168C (en) | 2008-01-09 |
Family
ID=36906648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100227143A Active CN100360168C (en) | 2005-12-14 | 2005-12-14 | Chinese medicine composition for diminishing speckle and pox |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100360168C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101461529B (en) * | 2009-01-14 | 2013-02-06 | 邢炳荣 | Health-care food for nourishing face, moistening skin and eliminating spot |
| CN104587353A (en) * | 2015-02-14 | 2015-05-06 | 刘相明 | Medicament for treating scar |
| CN104663938A (en) * | 2013-11-27 | 2015-06-03 | 武汉卡倍欣科技发展有限公司 | Freckle-removing feature-beautifying tea |
| CN106036850A (en) * | 2016-06-07 | 2016-10-26 | 成长动力（中国）股份有限公司 | Traditional Chinese medicine health product having chloasma removing effect and preparation method thereof |
| CN107308377A (en) * | 2017-06-08 | 2017-11-03 | 张挺 | A kind of medicine of nti-freckle |
| CN108041368A (en) * | 2017-11-20 | 2018-05-18 | 宁国平衡健康管理有限公司 | A kind of Xuancheng's pawpaw beverage for improving chloasma |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107714765A (en) * | 2017-11-22 | 2018-02-23 | 中山市择朋生物科技有限公司 | A kind of mouth containing system of mourning product for nettle rash and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085789A (en) * | 1993-07-01 | 1994-04-27 | 陈文峰 | Honeysuckle flower liquid for treating comedo |
| CN1528212A (en) * | 2003-10-16 | 2004-09-15 | 晨 梁 | Food for removing chloasma |
-
2005
- 2005-12-14 CN CNB2005100227143A patent/CN100360168C/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101461529B (en) * | 2009-01-14 | 2013-02-06 | 邢炳荣 | Health-care food for nourishing face, moistening skin and eliminating spot |
| CN104663938A (en) * | 2013-11-27 | 2015-06-03 | 武汉卡倍欣科技发展有限公司 | Freckle-removing feature-beautifying tea |
| CN104587353A (en) * | 2015-02-14 | 2015-05-06 | 刘相明 | Medicament for treating scar |
| CN104587353B (en) * | 2015-02-14 | 2018-02-16 | 潍坊医学院 | A kind of medicine for treating scar |
| CN106036850A (en) * | 2016-06-07 | 2016-10-26 | 成长动力（中国）股份有限公司 | Traditional Chinese medicine health product having chloasma removing effect and preparation method thereof |
| CN107308377A (en) * | 2017-06-08 | 2017-11-03 | 张挺 | A kind of medicine of nti-freckle |
| CN108041368A (en) * | 2017-11-20 | 2018-05-18 | 宁国平衡健康管理有限公司 | A kind of Xuancheng's pawpaw beverage for improving chloasma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100360168C (en) | 2008-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1211107C (en) | Mixture for improving blood circulation | |
| CN1814216A (en) | Chinese medicine composition for diminishing speckle and pox | |
| CN1857642A (en) | Quality control method for depression relieving and tranquilizing preparation | |
| CN1233387C (en) | Chinese compound medicine for treating anhypnosis and its preparation metod | |
| CN1565552A (en) | Chinese traditional medicine for treating immune hypofunction and disfunction | |
| CN1698878A (en) | Kidney replenishing medicinal composition and its preparation process and novel use | |
| CN1225252C (en) | Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1297290C (en) | Medicinal composition for treating coronary heart disease and stenocardia and its preparation method | |
| CN1535700A (en) | Blood-supplementing medicine composition | |
| CN1314418C (en) | Medicine for clearing away lung-heat, eliminating phaegn, reliveing cough and asthma and its preparing method | |
| CN1651036A (en) | Angelica root mistletoe granules and its preparation method | |
| CN1290529C (en) | Medicine for treating gout, hyperuricemia and hyperlipemia and preparation method thereof | |
| CN1335161A (en) | Deer bone powder capsule | |
| CN100339092C (en) | Chinese medicine composition for treating apoplexy and its prepn process and use | |
| CN1857495A (en) | Compound chinese preparation for treating pain symptom and its preparing process | |
| CN1507352A (en) | Compound plant medicine and its application | |
| CN1069537C (en) | Medicine for weight-reducing and beautifying | |
| CN1283300C (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1222305C (en) | Chinese medicine for treating liver-kidney insufficiency, qi and yin vacuity and its preparation method | |
| CN1102061C (en) | Enqlish yew-manna tea | |
| CN1602945A (en) | Rhinitis treating soft medicinal capsule and preparation process thereof | |
| CN1593482A (en) | Medicine for treating hypomnesis of middle aged and old man and its preparation process | |
| CN1282470C (en) | Traditional Chinese medicine for anti depression | |
| CN1030275C (en) | Nutrient health composition for middle-aged and old people |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230703 Address after: 730050 No. 518, Dongping street, Qilihe district, Lanzhou City, Gansu Province Patentee after: Gansu Qingdai Chinese Herbal Medicine Beauty Research Co.,Ltd. Address before: 14 building, No. 237, Qingyang Road, Chengguan District, Gansu, Lanzhou, 730030 Patentee before: Jia Xiaorong |